Search

Displaying results 7081 - 7090 of 10000 in total
  1. Drug

    Resomelagon

    go.drugbank.com/drugs/DB21579
    Investigational

    Resomelagon is under investigation in clinical trial NCT06917001 (Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)). … The usage of the INN stem '-melagon' in the name indicates that Resomelagon is a non-peptidic melanocortin receptor agonist.

  2. Drug

    AAV-AIPL

    go.drugbank.com/drugs/DB17857
    Experimental

    AAV-AIPL is an adenovirus-associated viral vector serotype 8 containing the human _AIPL1_ gene. … Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.

    Synonyms: adenovirus associated viral vector serotype 8 containing the human AIPL1 gene
  3. Drug

    Melengestrol

    go.drugbank.com/drugs/DB11529
    ExperimentalVet approved

    An acylated derivative, melengestrol acetate, is used as a growth promoter in animals.

  4. Drug

    BMS-919373

    go.drugbank.com/drugs/DB15047
    Investigational

    BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).

  5. Drug

    Uracil mustard

    go.drugbank.com/drugs/DB00791
    Approved

    It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.

    Synonyms: 5-N,N-bis(2-chloroethyl)aminouracil
  6. Drug

    Recombinant Bacterial ACE2 Receptors-like Enzyme

    go.drugbank.com/drugs/DB15741
    Investigational

    ._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels.

  7. Drug

    Iratumumab

    go.drugbank.com/drugs/DB05550
    Investigational

    In phase I/II clinical trials for treatment of CD30+ lymphomas.

  8. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  9. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  10. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.